Serveur d'exploration sur la maladie de Parkinson

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Le cluster motor complications - wearing off

Terms

18motor complications
3wearing off
2efficacy
29motor fluctuations
22dyskinesias
17apomorphine
7freezing
9wearing‐off

Associations

Freq.WeightAssociation
20.272motor complications - wearing off
20.263efficacy - motor fluctuations
50.198dyskinesias - motor fluctuations
40.180apomorphine - motor fluctuations
20.161dyskinesias - freezing
30.151dyskinesias - motor complications
20.142dyskinesias - wearing‐off
20.124motor fluctuations - wearing‐off

Documents par ordre de pertinence
000638 (2010) Iria Cabo L Pez [Espagne] ; Pedro J. García Ruiz [Espagne] ; Silvia Vázquez Fernández Del Pozo [Espagne] ; Vicenta Sánchez Bernardos [Espagne]Motor complications in Parkinson's disease: Ten year follow‐up study
001450 (2005) Cheryl Waters [États-Unis]Other pharmacological treatments for motor complications and dyskinesias
001A69 (2001) J. Eric Ahlskog [États-Unis] ; Manfred D. Muenter [États-Unis]Frequency of levodopa‐related dyskinesias and motor fluctuations as estimated from the cumulative literature
000611 (2010) Olivier Rascol [France] ; Jean-Philippe Azulay [France] ; Olivier Blin [France] ; Anne-Marie Bonnet [France] ; Christine Brefel-Courbon [France] ; Pierre Césaro [France] ; Philippe Damier [France] ; Bérengère Debilly [France] ; Frank Durif [France] ; Monique Galitzky [France] ; Jean-Marie Grouin [France] ; Sylvie Pennaforte [France] ; Gabriel Villafane [France] ; Sadek Yaici [France] ; Yves Agid [France]Orodispersible sublingual piribedil to abort OFF episodes: A single dose placebo‐controlled, randomized, double‐blind, cross‐over study
000736 (2010) Bonnie P. Hersh [États-Unis] ; Nancy L. Earl [États-Unis] ; Robert A. Hauser [États-Unis] ; Mark Stacy [États-Unis]Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations
000C36 (2008) Fabrizio Stocchi [Italie] ; Michele Tagliati [États-Unis] ; C. Warren Olanow [États-Unis]Treatment of levodopa‐induced motor complications
000E08 (2008) Pedro J. García Ruiz [Espagne] ; Ángel Sesar Ignacio [Espagne] ; Bego A Ares Pensado [Espagne] ; Alfonso Castro García [Espagne] ; Fernando Alonso Frech [Espagne] ; Mercedes Álvarez L Pez [Espagne] ; José Arbelo González [Espagne] ; Joan Baiges Octavio [Espagne] ; Juan Andrés Burguera Hernández [Espagne] ; Matilde Calopa Garriga [Espagne] ; Dulce Campos Blanco [Espagne] ; Belén Casta O García [Espagne] ; Manuel Carballo Cordero [Espagne] ; José Chac N Pe A [Espagne] ; Anna Espino Ibá Ez [Espagne] ; Aránzazu Gorospe Onisalde [Espagne] ; Santiago Giménez-Roldán [Espagne] ; Pilar Granés Ibá Ez [Espagne] ; Jorge Hernández Vara [Espagne] ; Ram N Ibá Ez Alonso [Espagne] ; Félix Javier Jiménez Jiménez [Espagne] ; Jerzy Krupinski [Espagne] ; Jaime Kulisevsky Bojarsky [Espagne] ; Inés Legarda Ramírez [Espagne] ; Elena Lezcano García [Espagne] ; Juan Carlos Martínez-Castrillo [Espagne] ; Dolores Mateo González [Espagne] ; Francesc Miquel Rodríguez [Espagne] ; Pablo Mir [Espagne] ; Elena Mu Oz Fargas [Espagne] ; José Obeso Inchausti [Espagne] ; Jesús Olivares Romero [Espagne] ; José Olivé Plana [Espagne] ; Pilar Otermin Vallejo [Espagne] ; Berta Pascual Sedano [Espagne] ; Víctor Pérez De Colosía Rama [Espagne] ; Isabel Pérez L Pez-Fraile [Espagne] ; Albert Planas Comes [Espagne] ; Víctor Puente Periz [Espagne] ; María Cruz Rodríguez Oroz [Espagne] ; Dolores Sevillano García [Espagne] ; Pilar Solís Pérez [Espagne] ; José Suárez Mu Oz [Espagne] ; Julia Vaamonde Gamo [Espagne] ; Caridad Valero Merino [Espagne] ; Francesc Valldeoriola Serra [Espagne] ; José Miguel Velázquez Pérez [Espagne] ; Rosa Yá Ez Ba A [Espagne] ; Ivana Zamarbide Capdepon [Espagne]Efficacy of long‐term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: A multicenter study
000F33 (2007) Charlene Hoffman Snyder [États-Unis] ; Charles H. Adler [États-Unis]The patient with Parkinson’s disease: Part I–Treating the motor symptoms;Part II–Treating the nonmotor symptoms
000F43 (2007) Robert A. Hauser [États-Unis] ; Olivier Rascol [France] ; Amos D. Korczyn [Israël] ; A. Jon Stoessl [Canada] ; Ray L. Watts [États-Unis] ; Werner Poewe [Autriche] ; Peter P. De Deyn [Belgique] ; Anthony E. Lang [Canada]Ten‐year follow‐up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa
001169 (2006) Obering [États-Unis] ; Chen ; Swope [États-Unis]Update on Apomorphine for the Rapid Treatment of Hypomobility (“Off”) Episodes in Parkinson's Disease
001309 (2006) P. Odin [Allemagne] ; C. Oehlwein [Allemagne] ; A. Storch [Allemagne] ; U. Polzer [Allemagne] ; G. Werner [Allemagne] ; R. Renner [Allemagne] ; M. Shing [Allemagne] ; A. Ludolph [Allemagne] ; P. Schüler [Allemagne]Efficacy and safety of high‐dose cabergoline in Parkinson's disease
001349 (2006) Paolo Mazzone [Italie] ; Fabrizio Stocchi [Italie] ; Salvatore Galati [Italie] ; Angelo Insola [Italie] ; Maria Grazia Altibrandi [Italie] ; Nicola Modugno [Italie] ; Domenicantonio Tropepi [Italie] ; Livia Brusa [Italie] ; Alessandro Stefani [Italie]Bilateral Implantation of Centromedian‐Parafascicularis Complex and GPi: A New Combination of Unconventional Targets for Deep Brain Stimulation in Severe Parkinson Disease
001427 (2005) Leo Verhagen Metman [États-Unis] ; Shaun T. O'Leary [États-Unis]Role of surgery in the treatment of motor complications
001464 (2005) Joseph Jankovic [États-Unis]Motor fluctuations and dyskinesias in Parkinson's disease: Clinical manifestations
001481 (2005) Mark Stacy [États-Unis] ; Annette Bowron [Royaume-Uni] ; Mark Guttman [Canada] ; Robert Hauser [États-Unis] ; Kim Hughes [Royaume-Uni] ; Jan Petter Larsen [Norvège] ; Peter Lewitt [États-Unis] ; Wolfgang Oertel [Allemagne] ; Niall Quinn [Royaume-Uni] ; Kapil Sethi [États-Unis] ; Fabrizio Stocchi [Italie]Identification of motor and nonmotor wearing‐off in Parkinson's disease: Comparison of a patient questionnaire versus a clinician assessment
001516 (2005) Regina Katzenschlager [Royaume-Uni, Autriche] ; Andrew Hughes [Australie] ; Andrew Evans [Royaume-Uni] ; Alice J. Manson [Royaume-Uni] ; Marion Hoffman [Australie] ; Lesley Swinn [Royaume-Uni] ; Hilary Watt [Royaume-Uni] ; Kailash Bhatia [Royaume-Uni] ; Niall Quinn [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni]Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: A prospective study using single‐dose challenges
001557 (2004) Cheryl H. Waters [États-Unis] ; Kapil D. Sethi [États-Unis] ; Robert A. Hauser [États-Unis] ; Eric Molho [États-Unis] ; John M. Bertoni [États-Unis]Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: A 3‐month, randomized, placebo‐controlled study
001C39 (2000) Anette Schrag [Royaume-Uni] ; Niall Quinn [Royaume-Uni]Dyskinesias and motor fluctuations in Parkinson's disease
002357 (1995) D. Muguet [France] ; E. Broussolle [France] ; G. Chazot [France]Apomorphine in patients with Parkinson's disease
000095 (2011) Angelo Antonini [Italie] ; Pablo Martinez-Martin [Espagne] ; Ray K. Chaudhuri [Royaume-Uni] ; Marcelo Merello [Argentine] ; Robert Hauser [États-Unis] ; Regina Katzenschlager [Autriche] ; Per Odin [Allemagne] ; Mark Stacy [États-Unis] ; Fabrizio Stocchi [Italie] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Cristina Sampaio [Portugal] ; Anette Schrag [Royaume-Uni] ; Glenn T. Stebbins [États-Unis] ; Christopher G. Goetz [États-Unis]Wearing‐off scales in Parkinson's disease: Critique and recommendations
000213 (2011) Fabrizio Stocchi [Italie] ; Luigi Giorgi [Royaume-Uni] ; Brian Hunter [Royaume-Uni] ; Anthony Hv Schapira [Royaume-Uni]PREPARED: Comparison of prolonged and immediate release ropinirole in advanced Parkinson's disease
000246 (2011) Thomas Wichmann [États-Unis] ; Mahlon R. Delong [États-Unis] ; Jorge Guridi [Espagne] ; Jose A. Obeso [Espagne]Milestones in research on the pathophysiology of Parkinson's disease
000260 (2011) Rebecca Stowe [Royaume-Uni] ; Natalie Ives [Royaume-Uni] ; Carl E. Clarke [Royaume-Uni] ; Kelly Handley [Royaume-Uni] ; Alexandra Furmston [Royaume-Uni] ; Katherine Deane [Royaume-Uni] ; J. J. Van Hilten [Pays-Bas] ; Keith Wheatley [Royaume-Uni] ; Richard Gray [Royaume-Uni]Meta‐analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson's disease
000333 (2011) Olivier Rascol [France]Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged‐release
000349 (2011) Robert A. Hauser [États-Unis] ; Aaron L. Ellenbogen [États-Unis] ; Leo Verhagen Metman [États-Unis] ; Ann Hsu [États-Unis] ; Martin J. O'Connell [États-Unis] ; Nishit B. Modi [États-Unis] ; Hsuan-Ming Yao [États-Unis] ; Sherron H. Kell [États-Unis] ; Suneel K. Gupta [États-Unis]Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease
000363 (2011) Stephanie M. Van Rooden [Pays-Bas] ; Fabrice Colas [Pays-Bas] ; Pablo Martínez-Martín [Espagne] ; Martine Visser [Pays-Bas] ; Dagmar Verbaan [Pays-Bas] ; Johan Marinus [Pays-Bas] ; Ray K. Chaudhuri [Royaume-Uni] ; Joost N. Kok [Pays-Bas] ; Jacobus J. Van Hilten [Pays-Bas]Clinical subtypes of Parkinson's disease
000407 (2011) Daniela Berg [Allemagne] ; Jana Godau [Allemagne] ; Claudia Trenkwalder [Allemagne] ; Karla Eggert [Allemagne] ; Iiona Csoti [Allemagne] ; Alexander Storch [Allemagne] ; Heiko Huber [Allemagne] ; Monica Morelli-Canelo [Allemagne] ; Maria Stamelou [Allemagne] ; Vincent Ries [Allemagne] ; Martin Wolz [Allemagne] ; Christine Schneider [Allemagne] ; Thérèse Di Paolo [Canada] ; Fabrizio Gasparini [Suisse] ; Sam Hariry [Suisse] ; Marc Vandemeulebroecke [Suisse] ; Walid Abi-Saab [Suisse] ; Katy Cooke [Royaume-Uni] ; Donald Johns [Suisse] ; Baltazar Gomez-Mancilla [Suisse]AFQ056 treatment of levodopa‐induced dyskinesias: Results of 2 randomized controlled trials
000504 (2010) Tom H. Johnston [Canada] ; Susan H. Fox [Canada] ; Matthew J. Piggott [Australie] ; Juha-Matti Savola [Suisse] ; Jonathan M. Brotchie [Canada]The α2 adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates
000549 (2010) Karla Eggert [Allemagne] ; David Squillacote [États-Unis] ; Paolo Barone [Italie] ; Richard Dodel [Allemagne] ; Regina Katzenschlager [Autriche] ; Murat Emre [Turquie] ; Andrew Lees (neurologue) [Royaume-Uni] ; Olivier Rascol [France] ; Werner Poewe [Autriche] ; Eduardo Tolosa [Espagne] ; Claudia Trenkwalder [Allemagne] ; Marco Onofrj [Italie] ; Fabrizio Stocchi [Italie] ; Giuseppe Nappi [Italie] ; Vladimir Kostic [Serbie] ; Jagoda Potic [Serbie] ; Evzen Ruzicka [République tchèque] ; Wolfgang Oertel [Allemagne]Safety and efficacy of perampanel in advanced Parkinson's disease: A randomized, placebo‐controlled study
000652 (2010) Emanuele Cereda [Italie] ; Michela Barichella [Italie] ; Carlo Pedrolli [Italie] ; Gianni Pezzoli [Italie]Low‐protein and protein‐redistribution diets for Parkinson's disease patients with motor fluctuations: A systematic review
000654 (2010) Asha Kishore [Inde] ; Ravimohan Rao [Inde] ; Syam Krishnan [Inde] ; Dilip Panikar [Inde] ; Gangadhara Sarma [Inde] ; Mathuranath Pavagada Sivasanakaran [Inde] ; Sankara Sarma [Inde]Long‐term stability of effects of subthalamic stimulation in Parkinson's disease: Indian Experience
000838 (2010) Kerstin Ziegler [Allemagne] ; Frauke Schroeteler [Allemagne] ; Andres O. Ceballos-Baumann [Allemagne] ; Urban M. Fietzek [Allemagne]A new rating instrument to assess festination and freezing gait in Parkinsonian patients
000920 (2009) Leon Poltawski [Royaume-Uni] ; Hazel Edwards [Royaume-Uni] ; Amy Todd [Royaume-Uni] ; Tim Watson [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] ; Cherry Ann James [Royaume-Uni]Ultrasound treatment of cutaneous side‐effects of infused apomorphine: A randomized controlled pilot study
000937 (2009) M. M. Wickremaratchi [Royaume-Uni] ; Y. Ben-Shlomo [Royaume-Uni] ; H. R. Morris [Royaume-Uni]The effect of onset age on the clinical features of Parkinson’s disease
000968 (2009) Cecilia M. Peralta [Autriche, Argentine] ; Birgit Frauscher [Autriche] ; Klaus Seppi [Autriche] ; Elisabeth Wolf [Autriche] ; Gregor K. Wenning [Autriche] ; Birgit Högl [Autriche] ; Werner Poewe [Autriche]Restless legs syndrome in Parkinson's disease
000974 (2009) Giuseppe Frazzitta [Italie] ; Roberto Maestri [Italie] ; Davide Uccellini [Italie] ; Gabriella Bertotti [Italie] ; Paola Abelli [Italie]Rehabilitation treatment of gait in patients with Parkinson's disease with freezing: A comparison between two physical therapy protocols using visual and auditory cues with or without treadmill training
000A11 (2009) Giovanni Fabbrini [Italie] ; Giovanni Defazio [Italie] ; Carlo Colosimo [Italie] ; Antonio Suppa [Italie] ; Maria Bloise [Italie] ; Alfredo Berardelli [Italie]Onset and spread of dyskinesias and motor symptoms in Parkinson's disease
000A25 (2009) Sebastian Paus [Allemagne] ; Franziska Gadow [Allemagne] ; Michael Knapp [Allemagne] ; Christine Klein [Allemagne] ; Thomas Klockgether [Allemagne] ; Ullrich Wüllner [Allemagne]Motor complications in patients form the German Competence Network on Parkinson's disease and the DRD3 Ser9Gly polymorphism
000B01 (2009) C. Marin [Espagne] ; E. Aguilar [Espagne] ; G. Mengod [Espagne] ; R. Cortés [Espagne] ; J. A. Obeso [Espagne]Effects of early vs. late initiation of levodopa treatment in hemiparkinsonian rats
000B04 (2009) H. Nissinen [Finlande] ; M. Kuoppam Ki [Finlande] ; M. Leinonen [Suède] ; A. H. Schapira [Royaume-Uni]Early versus delayed initiation of entacapone in levodopa‐treated patients with Parkinson’s disease: a long‐term, retrospective analysis
000B30 (2009) D. Nyholm [Suède] ; R. Constantinescu [Suède] ; B. Holmberg [Suède] ; N. Dizdar [Suède] ; H. Askmark [Suède]Comparison of apomorphine and levodopa infusions in four patients with Parkinson’s disease with symptom fluctuations
000C27 (2008) Pablo Martinez-Martin [Espagne] ; Eduardo Tolosa [Espagne] ; Basilio Hernandez [Espagne] ; Xavier Badia [Espagne]Validation of the “QUICK” questionnaire—A tool for diagnosis of “wearing‐off” in patients with Parkinson's disease
000C50 (2008) Anthony H. V. Schapira [Royaume-Uni]The clinical relevance of levodopa toxicity in the treatment of Parkinson's disease
000C63 (2008) Robert A. Hauser [États-Unis] ; Lisa M. Shulman [États-Unis] ; Joel M. Trugman [États-Unis] ; John W. Roberts [États-Unis] ; Akihisa Mori [Japon] ; Rocco Ballerini [États-Unis] ; Neil M. Sussman [États-Unis]Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations
000D09 (2008) John G. Nutt [États-Unis]Pharmacokinetics and pharmacodynamics of levodopa
000D31 (2008) Maryka Quik [États-Unis] ; Kathryn O'Leary [États-Unis] ; Caroline M. Tanner [États-Unis]Nicotine and Parkinson's disease: Implications for therapy
000D61 (2008) C. Warren Olanow [États-Unis]Levodopa/dopamine replacement strategies in Parkinson's disease—Future directions
000D62 (2008) P. Damier [France] ; F. Viallet [France] ; M. Ziegler [France] ; I. Bourdeix [France] ; K. Rerat [France]Levodopa/DDCI and entacapone is the preferred treatment for Parkinson’s disease patients with motor fluctuations in routine practice: a retrospective, observational analysis of a large French cohort
000D83 (2008) Won Yong Lee [Corée du Sud] ; Won Tae Yoon [Corée du Sud] ; Hee Young Shin [Corée du Sud] ; Seong Hee Jeon [Corée du Sud] ; Poong-Lyul Rhee [Corée du Sud]Helicobacter pylori infection and motor fluctuations in patients with Parkinson's disease
000E32 (2008) Alice Nieuwboer [Belgique]Cueing for freezing of gait in patients with Parkinson's disease: A rehabilitation perspective
000E57 (2008) L. Bet [Italie] ; S. R. Bareggi [Italie] ; F. Pacei [Italie] ; G. Bondiolotti [Italie] ; G. Meola [Italie] ; A. H. V. Schapira [Royaume-Uni]Bimodal administration of entacapone in Parkinson’s disease patients improves motor control
000F19 (2007) Anne-Marie Willems [Belgique] ; Alice Nieuwboer [Belgique] ; Fabienne Chavret [Belgique] ; Kaat Desloovere [Belgique] ; René Dom [Belgique] ; Lynn Rochester [Royaume-Uni] ; Gert Kwakkel [Pays-Bas] ; Erwin Van Wegen [Pays-Bas] ; Diana Jones [Royaume-Uni]Turning in Parkinson's disease patients and controls: The effect of auditory cues
000F27 (2007) Fabio Blandini [Italie] ; Giovanna Levandis [Italie] ; Eleonora Bazzini [Italie] ; Giuseppe Nappi [Italie] ; Marie-Therese Armentero [Italie]Time‐course of nigrostriatal damage, basal ganglia metabolic changes and behavioural alterations following intrastriatal injection of 6‐hydroxydopamine in the rat: new clues from an old model
000F51 (2007) J. Herzog [Allemagne] ; M. Pinsker [Allemagne] ; M. Wasner [Allemagne] ; F. Steigerwald [Allemagne] ; S. Wailke [Allemagne] ; G. Deuschl [Allemagne] ; J. Volkmann [Allemagne]Stimulation of subthalamic fibre tracts reduces dyskinesias in STN‐DBS
000F56 (2007) V. Pursiainen [Finlande] ; T. J. Korpelainen [Finlande] ; H. T. Haapaniemi [Finlande] ; A. K. Sotaniemi [Finlande] ; V. V. Myllyl [Finlande]Selegiline and blood pressure in patients with Parkinson's disease
000F70 (2007) Vincent Paillé [France] ; Vincent Henry [France] ; Laurent Lescaudron [France] ; Philippe Brachet [France] ; Philippe Damier [France]Rat model of Parkinson's disease with bilateral motor abnormalities, reversible with levodopa, and dyskinesias
001058 (2007) Entacapone to tolcapone switch: Multicenter double‐blind, randomized, active‐controlled trial in advanced Parkinson's disease
001059 (2007) Günther Deuschl [Allemagne] ; Antanas Vaitkus [Lituanie] ; Gabriele-Cornelia Fox ; Torsten Roscher ; Dieter Schremmer [Allemagne] ; Ariel GordinEfficacy and tolerability of entacapone versus cabergoline in parkinsonian patients suffering from wearing‐off
001211 (2006) F. Stocchi [Italie]Rasagiline: defining the role of a novel therapy in the treatment of Parkinson's disease
001235 (2006) Wolfgang H. Oertel [Allemagne] ; Erik Wolters [Pays-Bas] ; Cristina Sampaio [Portugal] ; Santiago Gimenez-Roldan [Espagne] ; Bruno Bergamasco [Italie] ; Max Dujardin [France] ; Donald G. Grosset [Royaume-Uni] ; Guy Arnold [Allemagne] ; Klaus L. Leenders [Pays-Bas] ; Hans-Peter Hundemer [États-Unis] ; Alberto Lled [États-Unis] ; Andrew Wood [États-Unis] ; Paul Frewer [États-Unis] ; Johannes Schwarz [Allemagne]Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study
001339 (2006) D. De Gaspari [Italie] ; C. Siri [Italie] ; A. Landi [Italie] ; R. Cilia [Italie] ; A. Bonetti [Italie] ; F. Natuzzi [Italie] ; L. Morgante [Italie] ; C B Mariani [Italie] ; E. Sganzerla [Italie] ; G. Pezzoli [Italie] ; A. Antonini [Italie]Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson’s disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus
001360 (2006) Noël L. W. Keijsers [Pays-Bas] ; Martin W. I. M. Horstink [Pays-Bas] ; Stan C. A. M. Gielen [Pays-Bas]Ambulatory motor assessment in Parkinson's disease
001365 (2006) Vesna Sossi ; Rau L De La Fuente-Ferna Ndez [Espagne] ; Michael Schulzer ; John Adams [Canada] ; Jon StoesslAge-related differences in levodopa dynamics in Parkinson's: implications for motor complications
001428 (2005) Katherine L. Widnell [États-Unis] ; Cynthia Comella [États-Unis]Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations
001455 (2005) Charles H. Adler [États-Unis]Nonmotor complications in Parkinson's disease
001458 (2005) C. Warren Olanow [États-Unis] ; Joseph Jankovic [États-Unis]Neuroprotective therapy in Parkinson's disease and motor complications: A search for a pathogenesis‐targeted, disease‐modifying strategy
001480 (2005) Stéphane Chapuis [France] ; Lemlih Ouchchane [France] ; Olivier Metz [France] ; Laurent Gerbaud [France] ; Franck Durif [France]Impact of the motor complications of Parkinson's disease on the quality of life
001499 (2005) M. Péchevis [France] ; C. E. Clarke [Royaume-Uni] ; P. Vieregge [Allemagne] ; B. Khoshnood [France] ; C. Deschaseaux-Voinet [France] ; G. Berdeaux [France] ; M. Ziegler [France]Effects of dyskinesias in Parkinson's disease on quality of life and health‐related costs: a prospective European study
001530 (2005) L. Alvarez ; R. Macias ; G. Lopez ; E. Alvarez ; N. Pavon ; M. C. Rodriguez-Oroz ; J. L. Juncos ; C. Maragoto ; J. Guridi ; I. Litvan ; E. S. Tolosa ; W. Koller [États-Unis] ; J. Vitek ; M. R. Delong ; J. A. ObesoBilateral subthalamotomy in Parkinson's disease: initial and long-term response
001579 (2004) Jan C. M. Zijlmans [Royaume-Uni, Pays-Bas] ; Berengere Debilly [France] ; Olivier Rascol [France] ; Andrew Lees (neurologue) [Royaume-Uni] ; Franck Durif [France]Safety of entacapone and apomorphine coadministration in levodopa‐treated Parkinson's disease patients: Pharmacokinetic and pharmacodynamic results of a multicenter, double‐blind, placebo‐controlled, cross‐over study
001582 (2004) Gurutz Linazasoro [Espagne]Recent failures of new potential symptomatic treatments for parkinson's disease: Causes and solutions
001584 (2004) Connie Marras [Canada] ; Anthony Lang [Canada] ; Murray Krahn [Canada] ; George Tomlinson [Canada] ; Gary Naglie [Canada]Quality of life in early Parkinson's disease: Impact of dyskinesias and motor fluctuations
001612 (2004) Rau L De La Fuente-Ferna Ndez [Canada] ; Vesna Sossi [Canada] ; Zhigao Huang [Canada] ; Sarah Furtado [Canada] ; Jian-Qiang Lu [Canada] ; Donald B. Calne [Canada] ; Thomas J. Ruth [Canada] ; A. Jon Stoessl [Canada]Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias
001613 (2004) C. Warren Olanow [États-Unis] ; Yves Agid [France] ; Yoshi Mizuno [Japon] ; Alberto Albanese [Italie] ; U. Bonucelli [Italie] ; Philip Damier [France] ; Justo De Yebenes [Espagne] ; Oscar Gershanik [Argentine] ; Mark Guttman [Canada] ; F. Grandas [Espagne] ; Mark Hallett [États-Unis] ; Ole Hornykiewicz [Autriche] ; Peter Jenner [Royaume-Uni] ; R. Katzenschlager [Royaume-Uni] ; William J. Langston [États-Unis] ; Peter Lewitt [États-Unis] ; Eldad Melamed [Israël] ; M. A. Mena [Espagne] ; P. P. Michel [France] ; Catherine Mytilineou [États-Unis] ; Jose A. Obeso [Espagne] ; Werner Poewe [Autriche] ; Niall Quinn [Royaume-Uni] ; R. Raisman-Vozari [France] ; Ali H. Rajput [Canada] ; Olivier Rascol [France] ; Christina Sampaio [Portugal] ; Fabrizio Stocchi [Italie]Levodopa in the treatment of Parkinson's disease: Current controversies
001634 (2004) Bastiaan R. Bloem [Pays-Bas] ; Jeffrey M. Hausdorff [Israël, États-Unis] ; Jasper E. Visser [Pays-Bas] ; Nir Giladi [Israël]Falls and freezing of gait in Parkinson's disease: A review of two interconnected, episodic phenomena
001822 (2002) V. S. Kosti ; J. Marinkovi ; M. Svetel ; E. Stefanova ; S. Przedborski [États-Unis]The effect of stage of Parkinson’s disease at the onset of levodopa therapy on development of motor complications
001899 (2002) Karen Stergaard [Danemark] ; Niels Sunde [Danemark] ; Erik Dupont [Danemark]Effects of bilateral stimulation of the subthalamic nucleus in patients with severe Parkinson's disease and motor fluctuations
001926 (2002) Azi H. Rajput [Canada] ; Mark E. Fenton [Canada] ; Sam Birdi [Canada] ; Rob Macaulay [Canada] ; David George [Canada] ; Bohdar Rozdilsky [Canada] ; Lee C. Ang [Canada] ; Ambikaipakan Senthilselvan [Canada] ; Oleh Hornykiewicz [Autriche]Clinical–Pathological study of levodopa complications
001936 (2002) Alice J. Manson [Royaume-Uni] ; Kirsten Turner [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni]Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: Long‐term follow‐up study of 64 patients
001A90 (2001) Alberto Albanese [Italie] ; Ubaldo Bonuccelli [Italie] ; Christine Brefel [France] ; K. Ray Chaudhuri [Royaume-Uni] ; Carlo Colosimo [Italie] ; Tobias Eichhorn [Allemagne] ; Eldad Melamed [Israël] ; Pierre Pollak [France] ; Teus Van Laar [Pays-Bas] ; Mario Zappia [Italie]Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease
001C20 (2000) Arpesh Mehta [États-Unis] ; Kyriaki Thermos [Grèce] ; Marie-Françoise Chesselet [États-Unis]Increased behavioral response to dopaminergic stimulation of the subthalamic nucleus after nigrostriatal lesions
002523 (1993) E. Nicolle [France] ; Pierre Pollak [France] ; F. Serre-Debeauvais [France] ; P. Richard [France] ; Cl Gervason [France] ; E. Broussolle [France] ; M. Gavend [France]Pharmacokinetics of apomorphine in parkinsonian patients
002551 (1993) G. Masson [France] ; D. Mestre [France] ; O. Blin [France]Dopaminergic modulation of visual sensitivity in man
002553 (1993) Aj Lees [Royaume-Uni]Dopamine agonists in Parkinson's disease: a look at apomorphine
002B06 (1982) Lodovico Frattola [Italie] ; Maria Grazia Albizzati [Italie] ; Sirio Bassi [Italie] ; Carlo Ferrarese [Italie] ; Marco Trabucchi [Italie]“On‐off” phenomena, dyskinesias and dystonias

Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 18:06:51 2016. Site generation: Wed Mar 6 18:46:03 2024